Key clinical point: The Melody transcatheter pulmonary valve showed the anticipated level of 5-year durability in a postapproval study.
Major finding: The 69% rate of freedom from valve hemodynamic failure at 5 years matched the 67% rate in the valve’s pivotal trial.
Study details: The Melody transcatheter pulmonary valve postapproval study, with 121 initial patients and 65 who were followed for 5 years.
Disclosures: The postapproval study was funded by Medtronic, the company that sells the Melody valve. Dr. Armstrong has received research funding from Medtronic as well as Abbott, Edwards, and Siemens, and she has been a consultant to Abbott.
REPORTING FROM SCAI 2019